LGL Partners LLC held its stake in Opko Health, Inc. (NASDAQ:OPK) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 47,507 shares of the biotechnology company’s stock at the end of the first quarter. LGL Partners LLC’s holdings in Opko Health were worth $380,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in the stock. National Planning Corp increased its stake in shares of Opko Health by 1.2% in the fourth quarter. National Planning Corp now owns 16,240 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 200 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Opko Health by 6.5% in the first quarter. Envestnet Asset Management Inc. now owns 16,356 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 1,001 shares in the last quarter. Formidable Asset Management LLC increased its stake in shares of Opko Health by 10.4% in the fourth quarter. Formidable Asset Management LLC now owns 11,638 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 1,096 shares in the last quarter. Capstone Asset Management Co. increased its stake in shares of Opko Health by 8.6% in the first quarter. Capstone Asset Management Co. now owns 17,646 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 1,400 shares in the last quarter. Finally, Pinnacle Associates Ltd. increased its stake in shares of Opko Health by 3.8% in the first quarter. Pinnacle Associates Ltd. now owns 49,603 shares of the biotechnology company’s stock valued at $397,000 after buying an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 23.66% of the company’s stock.
Opko Health, Inc. (NASDAQ OPK) traded up 1.24% during trading on Friday, reaching $6.53. The company’s stock had a trading volume of 3,929,136 shares. The company’s market cap is $3.65 billion. The stock has a 50-day moving average price of $6.76 and a 200 day moving average price of $8.36. Opko Health, Inc. has a 52-week low of $5.99 and a 52-week high of $12.15.
Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. The firm had revenue of $296.10 million for the quarter, compared to the consensus estimate of $313.36 million. During the same period last year, the firm earned ($0.02) EPS. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. On average, analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Opko Health, Inc. (OPK) Stake Held by LGL Partners LLC” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/06/16/opko-health-inc-opk-stake-maintained-by-lgl-partners-llc-updated-updated.html.
Several analysts recently weighed in on OPK shares. Guggenheim started coverage on Opko Health in a research report on Tuesday, March 14th. They set a “buy” rating and a $25.00 price objective for the company. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $19.50 price objective on shares of Opko Health in a research report on Tuesday, June 6th. Standpoint Research restated a “buy” rating and set a $14.00 price objective on shares of Opko Health in a research report on Sunday, March 5th. Finally, Jefferies Group LLC dropped their target price on Opko Health from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Thursday, March 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. Opko Health currently has an average rating of “Hold” and an average target price of $15.64.
In related news, Vice Chairman Jane Ph D. Hsiao bought 40,000 shares of the stock in a transaction dated Wednesday, May 10th. The stock was bought at an average price of $6.97 per share, with a total value of $278,800.00. Following the purchase, the insider now owns 24,723,133 shares in the company, valued at approximately $172,320,237.01. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Phillip Md Et Al Frost bought 11,000 shares of the stock in a transaction dated Monday, March 20th. The stock was bought at an average cost of $7.99 per share, with a total value of $87,890.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $24,520,918.49. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 2,698,000 shares of company stock valued at $18,464,543. Corporate insiders own 40.74% of the company’s stock.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.